**No vaccine against hantavirus is expected to receive regulatory approval or become widely available by the end of 2026.** Multiple candidates, including mRNA platforms from Moderna in collaboration with Korea University and single-dose mRNA constructs from UTMB, have shown strong preclinical protection in animal models against strains like Andes virus, while older DNA vaccines have completed limited Phase 1 safety and immunogenicity testing. However, all remain at early stages with no large-scale human efficacy trials underway or completed as of September 2026. Standard development timelines from preclinical work to licensure span many years, and the virus’s strain diversity plus low baseline incidence further limit acceleration. Recent outbreaks have heightened research interest, but official monitoring bodies report no approved human vaccines outside limited use of older inactivated products in parts of Asia for specific strains. A sudden emergency-use pathway could theoretically shift outcomes, yet current conditions make this improbable before year-end.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於Hantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
3% 機率
$139,010 交易量
$139,010 交易量
2026-12-31
3% 機率
$139,010 交易量
$139,010 交易量
2026-12-31
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**No vaccine against hantavirus is expected to receive regulatory approval or become widely available by the end of 2026.** Multiple candidates, including mRNA platforms from Moderna in collaboration with Korea University and single-dose mRNA constructs from UTMB, have shown strong preclinical protection in animal models against strains like Andes virus, while older DNA vaccines have completed limited Phase 1 safety and immunogenicity testing. However, all remain at early stages with no large-scale human efficacy trials underway or completed as of September 2026. Standard development timelines from preclinical work to licensure span many years, and the virus’s strain diversity plus low baseline incidence further limit acceleration. Recent outbreaks have heightened research interest, but official monitoring bodies report no approved human vaccines outside limited use of older inactivated products in parts of Asia for specific strains. A sudden emergency-use pathway could theoretically shift outcomes, yet current conditions make this improbable before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
市場開放時間： May 4, 2026, 10:39 AM ET
交易量
$139,010結束日期
2027-01-01市場開放時間
May 4, 2026, 10:39 AM ETThis market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**No vaccine against hantavirus is expected to receive regulatory approval or become widely available by the end of 2026.** Multiple candidates, including mRNA platforms from Moderna in collaboration with Korea University and single-dose mRNA constructs from UTMB, have shown strong preclinical protection in animal models against strains like Andes virus, while older DNA vaccines have completed limited Phase 1 safety and immunogenicity testing. However, all remain at early stages with no large-scale human efficacy trials underway or completed as of September 2026. Standard development timelines from preclinical work to licensure span many years, and the virus’s strain diversity plus low baseline incidence further limit acceleration. Recent outbreaks have heightened research interest, but official monitoring bodies report no approved human vaccines outside limited use of older inactivated products in parts of Asia for specific strains. A sudden emergency-use pathway could theoretically shift outcomes, yet current conditions make this improbable before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
交易量
$139,010結束日期
2027-01-01市場開放時間
May 4, 2026, 10:39 AM ET**No vaccine against hantavirus is expected to receive regulatory approval or become widely available by the end of 2026.** Multiple candidates, including mRNA platforms from Moderna in collaboration with Korea University and single-dose mRNA constructs from UTMB, have shown strong preclinical protection in animal models against strains like Andes virus, while older DNA vaccines have completed limited Phase 1 safety and immunogenicity testing. However, all remain at early stages with no large-scale human efficacy trials underway or completed as of September 2026. Standard development timelines from preclinical work to licensure span many years, and the virus’s strain diversity plus low baseline incidence further limit acceleration. Recent outbreaks have heightened research interest, but official monitoring bodies report no approved human vaccines outside limited use of older inactivated products in parts of Asia for specific strains. A sudden emergency-use pathway could theoretically shift outcomes, yet current conditions make this improbable before year-end.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions